NouvSoma 001
Alternative Names: Human-induced neural stem cell-derived extracellular vesicles; NouvSoma-001Latest Information Update: 11 Apr 2025
At a glance
- Originator iRegene Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Stroke
Most Recent Events
- 28 Mar 2025 Phase-I clinical trials in Stroke in China (IV) (NCT06612710)
- 01 Oct 2024 iRegene Therapeutics plans a phase I trial in Neuromyelitis Optica in China (Intrathecal) in November 2024 (NCT06620809)
- 25 Sep 2024 iRegene Therapeutics plans a phase I trial for Stroke in China (NCT06612710)